HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 4, 2013, Pages 531-542

  He, Min ^a   Zhang, Bin ^a   Wei, Xinbing ^a   Wang, Ziying ^a   Fan, Baoxia ^a   Du, Pengchao ^a   Zhang, Yan ^a   Jian, Wencheng ^b   Chen, Lin ^a   Wang, Linlin ^a   Fang, Hao ^c   Li, Xiang ^a   Wang, Ping An ^a   Yi, Fan ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Histone deacetylase; HMGB1; Reactive oxygen species; Stroke

Indexed keywords

HBP1 PROTEIN, RAT; HDAC4 PROTEIN, RAT; HDAC5 PROTEIN, RAT; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL; APOPTOSIS; ARTICLE; BRAIN; CEREBRAL ARTERY DISEASE; ENZYMOLOGY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; APOPTOSIS; BRAIN; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HMGB1 PROTEIN; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NADPH OXIDASE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84877015491     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12040     Document Type: Article

References (58)

1. Sierra C, Coca A, Schiffrin EL. Vascular mechanisms in the pathogenesis of stroke. Curr Hypertens Rep. 2011; 13: 200-7.
2. Auriel E, Bornstein NM. Neuroprotection in acute ischemic stroke-current status. J Cell Mol Med. 2010; 14: 2200-2.
3. Qureshi IA, Mehler MF. The emerging role of epigenetics in stroke: III. Neural stem cell biology and regenerative medicine. Arch Neurol. 2011; 68: 294-302.
4. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003; 19: 286-93.
5. Shakespear MR, Halili MA, Irvine KM, et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011; 32: 335-43.
6. Shein NA, Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol Med. 2011; 17: 448-56.
7. Venkataramani V, Rossner C, Iffland L, et al. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem. 2010; 285: 10678-89.
8. Chuang DM, Leng Y, Marinova Z, et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009; 32: 591-601.
9. Fischer A, Sananbenesi F, Mungenast A, et al. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci. 2010; 31: 605-17.
10. Kim GS, Jung JE, Niizuma K, et al. CK2 is a novel negative regulator of NADPH oxidase and a neuroprotectant in mice after cerebral ischemia. J Neurosci. 2009; 29: 14779-89.
11. Chen H, Song YS, Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab. 2009l; 29: 1262-72.
12. Sun GY, Horrocks LA, Farooqui AA. The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J Neurochem. 2007; 103: 1-16.
13. Kahles T, Luedike P, Endres M, et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke. 2007; 38: 3000-6.
14. Oka S, Ago T, Kitazono T, et al. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med. 2009; 87: 785-91.
15. Doyle K, Fitzpatrick FA. Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J Biol Chem. 2010; 285: 17417-24.
16. Wang ZY, Wei XB, Chen L, et al. Neuroprotective effects of hydroxyethylpuerarin against focal cerebral ischemia-reperfusion in rats. Chin J Physiol. 2007; 50: 211-6.
17. Zhang Y, Wei X, Liu L, et al. TIPE2, a novel regulator of immunity, protects against experimental stroke. J Biol Chem. 2012; 287: 32546-55.
18. Mocco J, Mack WJ, Ducruet AF, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res. 2006; 99: 209-17.
19. Wu CL, Chou YH, Chang YJ, et al. Interplay between cell migration and neurite outgrowth determines SH2B1beta-enhanced neurite regeneration of differentiated PC12 cells. PLoS ONE. 2012; 7: e34999.
20. Wang Z, Wei X, Zhang Y, et al. NADPH oxidase-derived ROS contributes to upregulation of TRPC6 expression in puromycin aminonucleoside-induced podocyte injury. Cell Physiol Biochem. 2009; 24: 619-26.
21. Li N, Yi F, Sundy CM, et al. Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys. Am J Physiol Renal Physiol. 2007; 292: F207-16.
22. Zhang S, Zhang Y, Wei X, et al. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta. 2010; 1802: 1078-86.
23. Yi F, Zhang AY, Janscha JL, et al. Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int. 2004; 66: 1977-87.
24. Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res. 2009; 15: 4401-14.
25. Zhang J, Takahashi HK, Liu K, et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke. 2011; 42: 1420-8.
26. Lai YL, Smith PM, Lamm WJ, et al. Sampling and analysis of cerebrospinal fluid for chronic studies in awake rats. J Appl Physiol. 1983; 54: 1754-7.
27. Tang XN, Cairns B, Cairns N, et al. Apocynin improves outcome in experimental stroke with a narrow dose range. Neuroscience. 2008; 154: 556-62.
28. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 2007; 321: 892-901.
29. Wang Z, Leng Y, Tsai LK, et al. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab. 2011; 31: 52-7.
30. Ren M, Leng Y, Jeong M, et al. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem. 2004; 89: 1358-67.
31. Evankovich J, Cho SW, Zhang R, et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem. 2010; 285: 39888-97.
32. Ma C, D'Mello SR. Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. J Biol Chem. 2011; 286: 4819-28.
33. Kim D, Frank CL, Dobbin MM, et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron. 2008; 60: 803-17.
34. Levy RM, Mollen KP, Prince JM, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol. 2007; 293: R1538-44.
35. Majdzadeh N, Wang L, Morrison BE, et al. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol. 2008; 68: 1076-92.
36. Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science. 2009; 323: 256-9.
37. Tsankova NM, Berton O, Renthal W, et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006; 9: 519-25.
38. Renthal W, Maze I, Krishnan V, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron. 2007; 56: 517-29.
39. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005; 120: 483-95.
40. Fan J, Li Y, Levy RM, et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol. 2007; 178: 6573-80.
41. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5: 331-42.
42. Mollnes TE. High mobility group box-1 protein-one step closer to the clinic? Crit Care. 2008; 12: 168.
43. Yang QW, Wang JZ, Li JC, et al. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab. 2010; 30: 243-54.
44. Qiu J, Xu J, Zheng Y, et al. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke. 2010; 41: 2077-82.
45. Kim JB, Sig Choi J, Yu YM, et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci. 2006; 26: 6413-21.
46. Liu K, Mori S, Takahashi HK, et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. 2007; 21: 3904-16.
47. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003; 22: 5551-60.
48. Cokol M, Nair R, Rost B. Finding nuclear localization signals. EMBO Rep. 2000; 1: 411-5.
49. Nakka VP, Gusain A, Mehta SL, et al. Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol. 2008; 37: 7-38.
50. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999; 79: 1431-568.
51. Ferrer I, Planas AM. Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol. 2003; 62: 329-39.
52. Nicotera P, Leist M, Ferrando-May E. Intracellular ATP, a switch in the decision between apoptosis and necrosis. Toxicol Lett. 1998; 102-103: 139-42.
53. Kikuchi K, Kawahara K, Tancharoen S, et al. The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther. 2009; 329: 865-74.
54. Zhou X, Marks PA, Rifkind RA, et al. Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA. 2001; 98: 10572-7.
55. Milde T, Oehme I, Korshunov A, et al. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010; 16: 3240-52.
56. Zhang X, Chen HM, Jaramillo E, et al. Histone deacetylase-related protein inhibits AES-mediated neuronal cell death by direct interaction. J Neurosci Res. 2008; 86: 2423-31.
57. Bellenguez C, Bevan S, Gschwendtner A, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet. 2012; 44: 328-33.
58. Hacke W, Grond-Ginsbach C. Commentary on a GWAS: HDAC9 and the risk for ischaemic stroke. BMC Med. 2012; 10: 70.